Radalbuvir

Radalbuvir
Clinical data
Other namesGS-9669
Legal status
Legal status
Identifiers
IUPAC name
  • 5-(3,3-Dimethylbut-1-yn-1-yl)-3-{(1R)-N-[(1s,4s)-4-hydroxy-4-({[(3S)-oxolan-3-yl]oxy}methyl)cyclohexyl]-4-methylcyclohex-3-ene-1-carboxamido}thiophene-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC30H41NO6S
Molar mass543.72 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CC[C@@H](CC1)C(=O)N([C@H]2CC[C@](CC2)(O)CO[C@@H]3COCC3)c4c(sc(c4)C#CC(C)(C)C)C(=O)O
InChI
  • InChI=1S/C30H41NO6S/c1-20-5-7-21(8-6-20)27(32)31(25-17-24(11-13-29(2,3)4)38-26(25)28(33)34)22-9-14-30(35,15-10-22)19-37-23-12-16-36-18-23/h5,17,21-23,35H,6-10,12,14-16,18-19H2,1-4H3,(H,33,34)/t21-,22-,23-,30+/m0/s1
  • Key:MUICUPWICXUNRS-GDCCIXDYSA-N

Radalbuvir (INN,[1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials.[2] It targets NS5B polymerase.[3]

References

  1. ↑ "International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 28 (4). 2014.
  2. ↑ "Search of: GS-9669 — List Results". ClinicalTrials.gov.
  3. ↑ Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR (March 2018). "NS5B polymerase inhibitors in phase II clinical trials for HCV infection". Expert Opinion on Investigational Drugs. 27 (3): 243–250. doi:10.1080/13543784.2018.1420780. PMID 29271672.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.